Physician profile
Brian L Gallagher
NPI 1336358324
$4,049.58
in general payments reported to CMS, 2019-2025
37 companies · $410 in 2025
The $410 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $756 · 2020: $164 · 2021: $692 · 2022: $711 · 2023: $387 · 2024: $931 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,563 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,562.68 |
| Education | $164.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $644.20 | 2019-2024 | |
| Teleflex LLC | $459.42 | 2021-2022 | |
| Dornier Medtech America, INC | $314.26 | 2019-2024 | Dornier Medtech |
| Astellas Pharma US INC | $275.43 | 2019-2024 | Xtandi |
| Sumitomo Pharma America, INC. | $254.54 | 2024-2025 | Orgovyx, Gemtesa |
| Janssen Biotech, INC. | $194.24 | 2019-2023 | Erleada |
| Intuitive Surgical, INC. | $183.64 | 2019-2021 | |
| Abbvie INC. | $149.21 | 2019-2025 | |
| Paragon 28, INC. | $138.79 | 2022 | |
| Karl Storz Endoscopy-America | $121.87 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $120.36 | 2022-2025 | Keytruda, Bridion |
| Medtronic, INC. | $117.01 | 2021-2025 | Altaviva |
| Neotract INC. | $110.11 | 2019 | |
| Dendreon Pharmaceuticals LLC | $106.05 | 2023-2024 | Provenge |
| Olympus America INC. | $90.83 | 2019-2024 | Hd Camera Head, Uretero-Reno Videoscope |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $77.12 | 2023-2024 | Aquabeam System, Aquabeam Robotic System |
| Cook Medical LLC | $70.84 | 2024-2025 | S~Curve, Litho 150, Resonance |
| Myriad Genetic Laboratories, INC. | $63.31 | 2021-2023 | Prolaris |
| Axonics, INC. | $62.61 | 2022-2023 | Axonics, Bulkamid |
| Coloplast Corp | $55.00 | 2020-2022 | |
| Urogen Pharma, INC. | $53.25 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $50.24 | 2019-2025 | Adstiladrin |
| Bayer Healthcare Pharmaceuticals INC. | $41.21 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $34.54 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $33.08 | 2023-2024 | Opdivo |
| Conmed Corporation | $32.63 | 2024 | Airseal |
| Calyxo, INC. | $25.44 | 2025 | Cvac Aspiration System |
| Allergan, INC. | $20.41 | 2019 | |
| 180 Medical, INC. | $20.13 | 2022 | |
| Pfizer INC. | $19.08 | 2024 | |
| Amgen INC. | $18.28 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $16.81 | 2025 | |
| Travere Therapeutics, INC. | $16.76 | 2021 | |
| Convatec INC. | $15.35 | 2023 | |
| Endo Pharmaceuticals INC. | $14.81 | 2023 | Aveed, Xiaflex |
| Endo USA, INC. | $14.55 | 2024 | Xiaflex |
| Progenics Pharmaceuticals, INC. | $14.17 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Gallagher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.